Corporate ActionMay 14, 2026, 07:02 AM
XORTX Therapeutics Prices Public Offering at $1.88 for $5M Gross Proceeds
AI Summary
XORTX Therapeutics Inc. announced the pricing of a public offering of 2,659,574 common shares or pre-funded warrants at US$1.88 per share/warrant. This offering is expected to generate gross proceeds of US$5 million before deducting placement agent's fees and other expenses. The pre-funded warrants are immediately exercisable with an exercise price of US$0.0001 per share. The offering is anticipated to close around May 15, 2026, subject to customary closing conditions and regulatory approvals.
Key Highlights
- Public offering priced at US$1.88 per common share or pre-funded warrant.
- Gross proceeds expected to be US$5 million before deducting expenses.
- Offering includes 2,659,574 common shares or common share equivalents.
- Pre-funded warrants have an exercise price of US$0.0001 per share.
- The offering is expected to close on or about May 15, 2026.
- E.F. Hutton & Co. is acting as the exclusive placement agent for the offering.
Price Impact
More from XRTX